Michael Wiederhorn


Oppenheimer’s Michael Wiederhorn Remains Positive on Community Health Systems (CYH) Despite Disappointing Earnings

Community Health Systems (NYSE:CYH) shared tumbled nearly 26% today, after the hospital company reported a surprising loss for the fourth-quarter. However, Oppenheimer analyst Michael Wiederhorn …

Oppenheimer Maintains Outperform On Envision Healthcare Holdings Following Business Updates

In a research report published today, Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating on Envision Healthcare Holdings (NYSE:EVHC) with a $44.00 price …

Oppenheimer Maintains Outperform On Community Health Systems, Sees 19% Upside

Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating on Community Health Systems (NYSE:CYH) with a price target of $60.00, which represents a potential …

Oppenheimer Reiterates Outperform On Community Health Systems, $60 PT

In a research report released today, Oppenheimer analyst Michael Wiederhorn reiterated an Outperform rating on Community Health Systems (NYSE:CYH) with a $60, which represents …

Oppenheimer Assigns Outperform On HCA Holdings, $84 PT

In a research report issued today, Oppenheimer analyst Michael Wiederhorn assigned an Outperform rating on HCA Holdings Inc (NYSE:HCA) with a price target …

Oppenheimer Reiterates Outperform On Centene Shares, $99 PT

In a research report issued today, Oppenheimer analyst Michael Wiederhorn reiterated an Outperform rating on Centene (NYSE:CNC) with a price target of $99.00.

Oppenheimer Maintains Perform On Shares Of Aetna Following 3Q14 Results

In a research report issued today, Oppenheimer analyst Michael Wiederhorn maintained a Perform rating on Aetna (NYSE:AET). No price target was provided.

LHC Group: The Stock Remains Well-Positioned, Says Oppenheimer

In a research report issued today to investors, Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating on LHC Group (NASDAQ:LHCG) with a $27 …

Oppenheimer Remains Bullish On Chemed Following Meetings With Management; Raises PT To $115

In a research report issued today, Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating on Chemed (NYSE:CHE) and raised his price target to $115 …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts